Anavex Life Sciences Corp.
AVXL
$2.76
-$0.10-3.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -54.07% | 11.16% | 11.38% | 25.18% | 16.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -67.73% | -27.94% | -16.33% | 0.34% | 9.19% |
| Operating Income | 67.73% | 27.94% | 16.33% | -0.34% | -9.19% |
| Income Before Tax | 73.00% | 27.73% | 14.11% | -7.85% | -15.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 72.97% | 27.69% | 14.08% | -7.85% | -15.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.97% | 27.69% | 14.08% | -7.85% | -15.99% |
| EBIT | 67.73% | 27.94% | 16.33% | -0.34% | -9.19% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 73.27% | 29.68% | 15.81% | -5.73% | -13.03% |
| Normalized Basic EPS | 73.31% | 29.73% | 15.82% | -5.75% | -12.88% |
| EPS Diluted | 72.73% | 28.80% | 14.92% | -6.69% | -14.01% |
| Normalized Diluted EPS | 73.26% | 29.73% | 15.82% | -5.75% | -12.88% |
| Average Basic Shares Outstanding | 5.95% | 4.06% | 2.61% | 2.18% | 2.72% |
| Average Diluted Shares Outstanding | 6.01% | 4.06% | 2.61% | 2.18% | 2.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |